All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

New Funding and Approval Pathways Prove Popular

November 2, 2013
By Rita C. Peters
News
Article
Pharmaceutical TechnologyPharmaceutical Technology-11-02-2013
Volume 37
Issue 11

The JOBS Act and FDASIA show early signs of accelerating drug development.

Compared to other manufacturing and technology industries, the bio/pharmaceutical industry has one of the longest product development timelines. The research, development, testing, and regulatory review process typically extends for more than a decade, often exhausting the financial resources and commitment of investors. For patients with unmet medical needs, the wait for an effective therapy can be long, frustrating, and even life threatening. Late-stage failures of promising drugs can be devastating to the developer and patient alike.

Bio/pharmaceutical companies continue to explore different research, collaboration, and funding strategies in the search for ways to accelerate drug development. Assistance may be coming from an unlikely source: US Congress.

The 16-day shutdown of the US government demonstrated the divisiveness and dysfunction that has characterized Congress. More than half of all FDA employees were furloughed; research programs stalled at National Institutes of Health; and investigators at the Centers for Disease Control were not available to track outbreaks of infectious diseases. However, two pieces of legislation that took effect in 2012 are showing signs of having a positive impact on bio/pharmaceutical development, encouraging business growth, and hopefully resulting in improved patient access to effective drugs.

The Jumpstart Our Business Startups (JOBS) Act, signed into law in April 2012, gives emerging growth companies an easier path to raise capital privately or to seek public financing. It also reduces financial regulatory and compliance burdens on certain new public companies, enabling them to focus more on scientific research and less on financial reporting. The Biotechnology Industry Organization (BIO) reports that more than 40 biotech companies have gone public using provisions available through the JOBS Act (1).

The Food and Drug Administration Safety and Innovation Act (FDASIA), which included reauthorization of the Prescription Drug User Fee Act through September 2017, also provided for the timely review of new drug and biologic license applications. Since the legislation took effect in October 2012, the Pharmaceutical Research and Manufacturers Association, BIO, and drug companies have commended FDA for improved communication and collaboration with sponsors. FDA’s breakthrough therapy designation was developed to expedite the development and review of drugs for serious or life-threatening conditions and provide more intensive FDA guidance on an efficient drug-development program. Other expedited programs are fast track designation, accelerated approval, and priority review. Although no drugs have been approved under the new designations, the pathways are proving to be popular.

In fiscal year 2013, the Center for Drug Evaluation and Research received 92 breakthrough requests, approved 27, and denied 41; the remaining requests are pending approval. For almost 98% of the requests, action was taken within 60 days of receipt of the request. The Center for Biologics Evaluation and Research denied 8 of the 10 requests it received through Aug. 31, 2013 (2).

Both the JOBS Act and FDASIA passed with bipartisan support. In a few months, as members of Congress engage in the next round of budget and debt-ceiling debates, perhaps they should take a lesson from these bipartisan efforts and reach a consensus that makes sense for the nation as a whole.

Sources
1. BioTechNow blog, Jobs Act Deconstructed, accessed Oct. 21, 2013.
2. FDA, Frequently Asked Questions: Breakthrough Therapies, www.fda.gov, accessed Oct. 21, 2013.

 

About the Author
Rita Peters is the editorial director of BioPharm International.

Articles in this issue

Report from Brazil November 2013
Report from Brazil November 2013
Applying Catalysis to Optimize API Synthesis
Applying Catalysis to Optimize API Synthesis
Predicting Long-Term Storage Stability of Therapeutic Proteins
NEW_Keitel_passport-photo-827678-1408529973903.jpg
Control of Elemental Impurities
Automation System Improves Operational Insight
Automation System Improves Operational Insight
Eric_Langer_Headshot-827773-1408529855530.jpg
Disposable Applications in Demand by Biopharma
Solvent-Free Coating of Traditional and User-Friendly Dosage Forms
Solvent-Free Coating of Traditional and User-Friendly Dosage Forms
Wechsler_Jill-827676-1408529978030.jpg
Congress Revises Rules for Drug Compounding and Supply-Chain Security
Can Pharma Defy Gravity at the Patent Cliff?
Can Pharma Defy Gravity at the Patent Cliff?
NEW_Troubleshooting-827681-1408529966388.jpg
Defining and Presenting Overkill Cycle Validation
Preparing for Patent Expiry
Wireless Network Monitors Air Cooled Heat Exchanger
Wireless Network Monitors Air Cooled Heat Exchanger
Database Improves Process Efficiency
Database Improves Process Efficiency
System Links Packaging Operations
System Links Packaging Operations
Milmo_Sean-827677-1408529975535.jpg
European Union Introduces GMPs for Excipients
Recent Videos
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Related Content

Old rusty shovel in the ground on the building | Image Credit: © photolink - stock.adobe.com

Piramal Pharma Holds Groundbreaking at Kentucky Facility, Part of $90 Million Investment Plan

Patrick Lavery
July 2nd 2025
Article

The expansion of the Kentucky site accounts for $80 million of the announced investment, with the remaining money earmarked for facilities in Michigan.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


NÜRNBERG / GERMANY - APRIL 7, 2019: Siemens Logo on an office building in Nürnberg. Siemens is a German engineering company | Image Credit: © filmbildfabrik - stock.adobe.com

Siemens Finalizes $5.1B Dotmatics Acquisition

Christopher Cole
July 1st 2025
Article

Siemens expands AI-driven pharma software portfolio, integrating Dotmatics’ platform to connect drug research, development, and manufacturing digitally.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report

Susan Haigney
June 30th 2025
Article

The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.


Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Aenova Adds Cold Chain Warehouse to Latina, Italy Site

Susan Haigney
June 27th 2025
Article

The new building expands on the company’s supply chain solutions for biologics and temperature-sensitive pharmaceuticals.

Related Content

Old rusty shovel in the ground on the building | Image Credit: © photolink - stock.adobe.com

Piramal Pharma Holds Groundbreaking at Kentucky Facility, Part of $90 Million Investment Plan

Patrick Lavery
July 2nd 2025
Article

The expansion of the Kentucky site accounts for $80 million of the announced investment, with the remaining money earmarked for facilities in Michigan.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


NÜRNBERG / GERMANY - APRIL 7, 2019: Siemens Logo on an office building in Nürnberg. Siemens is a German engineering company | Image Credit: © filmbildfabrik - stock.adobe.com

Siemens Finalizes $5.1B Dotmatics Acquisition

Christopher Cole
July 1st 2025
Article

Siemens expands AI-driven pharma software portfolio, integrating Dotmatics’ platform to connect drug research, development, and manufacturing digitally.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report

Susan Haigney
June 30th 2025
Article

The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.


Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Aenova Adds Cold Chain Warehouse to Latina, Italy Site

Susan Haigney
June 27th 2025
Article

The new building expands on the company’s supply chain solutions for biologics and temperature-sensitive pharmaceuticals.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.